IL37 and inflammatory bowel disease: In line within this assumption, genetic inactivation or blockage of interleukin-23 (IL-23) knowingly absolutely required for the occurrence of Th17 cells in vivo were shown to mitigate colitis in preclinical model systems and be effective in treating IBD (5, 12, 13).